product image
Abingworth & Alebund’s Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal

May 11, 2021

Abingworth Achieves Financial Close, Raises USD 582 Million Abingworth, a London-based venture capital firm, has announced the closing of its new Clinical Co-Development Fu...

Read More
product image
Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic

May 6, 2021

Pfizer suffers a DMD delay and halts BCMA trials amid safety woes  Pfizer has paused after seeing three cases of peripheral neuropathy in an early-stage study, enrollm...

Read More
product image
MedTech Industry Roars Back as FDA Approvals Soar

May 4, 2021

Zimmer Biomet Receives FDA Approval for its Rosa System On 20 April 2021, Zimmer Biomet received FDA 510(k) clearance for its Rosa Partial Knee system for robotically-assis...

Read More
product image
Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med

Apr 29, 2021

Arch Oncology scores USD 105 Million for anti-CD47 med in solid tumors, multiple myeloma Arch Oncology scored USD 105 million from new and old backers to expand the drug’...

Read More
product image
Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Apr 22, 2021

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies ...

Read More
product image
Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO

Apr 15, 2021

Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced...

Read More
product image
Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Apr 13, 2021

Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M  Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading pa...

Read More
product image
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

Apr 6, 2021

Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. C...

Read More
product image
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Apr 1, 2021

Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront  Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, ...

Read More
product image
Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C

Mar 25, 2021

Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseas...

Read More
product image
Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche’s Tecentriq Results in NSCLC

Mar 23, 2021

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 respon...

Read More
product image
Valo Health receives $110M Series B Cognito’s therapy slows Alzheimer’s disease Ventyx Biosciences raises $114M Takeda expands immuno-oncology portfolio

Mar 11, 2021

Valo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug...

Read More
product image
Overwhelming success of Gilead/Kite’s Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio’s antibody-drug failure; Roche discards Tecentriq for bladder cancer

Mar 9, 2021

Gilead’s Kite Receives Expanded Approval for its CAR-T Yescarta’s in Follicular Lymphoma  Gilead’s Kite has successfully secured success in launching the...

Read More
product image
Novavax targets COVID-19 approval; Iktos collaborates with Pfizer; AbbVie bags option to acquire Mitokinin; Presage inks new pact with Merck

Mar 4, 2021

Novavax targets approval for the COVID-19 vaccine in the US Novavax is targeting a second-quarter FDA filing for emergency use of its COVID-19 vaccine. The aim hints the U....

Read More
product image
Evotec, Chinook Teams Up for CKD Therapy; HitGen & UPPTHERA in Drug Delivery Research; Artiva’s $120 M Coup of NK Cell Therapy; Junshi & AZ with Toripalimab in China

Mar 2, 2021

Evotec, Chinook Therapeutics to Advance Chronic Kidney Diseases Therapy Market Evotec and Chinook Therapeutics have collaborated to develop and discover precision medicine ...

Read More